CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have been tracked and traced, and close contacts isolated. We are pleased that there have been no further positive cases identified. A deep clean was undertaken at the facility and it continues to operate as usual with no interruption to the production of CSL’s lifesaving therapies and vaccines, including production of AstraZeneca vaccine at our Parkville site.
As a science-based company which includes the world’s second largest provider of influenza vaccines, we have a comprehensive understanding and appreciation for the public health value that vaccines provide. We therefore strongly encourage all of our people, their families and every Australian to get vaccinated against COVID-19.
- ends -
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL
For more information about CSL Limited, visit www.csl.com